An Indian origin researcher at The University of Texas M. D. Anderson
Cancer Center has identified the mechanism whereby a protein that fuels ovarian cancer can be shut down.
'The protein interleukin-8 (IL-8) is a potential therapeutic target
in ovarian cancer,' said Dr. Anil Sood, a professor in the M. D. Anderson Departments of Gynecologic Oncology and Cancer Biology.
Writing about the research team’s findings in a paper, published in the
Journal of the National Cancer Institute, Dr. Sood said that high IL-8
expression in tumours is associated with advanced tumour stage, and earlier death for ovarian cancer patients.
He revealed that experiments conducted on a mouse model had revealed
that short interfering RNA (siRNA) could cut IL-8 expression, and reduce tumour size by attacking its blood supply.
'This comprehensive analysis - with human data, animal data and lab
experiments to highlight the molecular mechanisms involved - helps us develop the new targets needed for a more effective approach against ovarian cancer,' Dr. Sood said.
Pointing out that IL-8 is over-expressed in many types of cancer, Dr. Sood added: 'In the long run, this research will have applications in other cancers as well.'
During the study, the researchers tested a specific siRNA against two
lines of ovarian cancer in a mouse model. They packaged siRNA that stymies IL-8 into a small ball of fat known as a liposome, a combination they developed because siRNA is hard to deliver to tumours.